InvestorQ : How soon can we expect COVID-19 production, now that Cadila, Reddy Labs and Syngene have also been licensed?
Crowny Pinto made post

How soon can we expect COVID-19 production, now that Cadila, Reddy Labs and Syngene have also been licensed?

Answer
user profile image
Aditi Sharma answered.
3 months ago


Gilead Sciences, the discoverer of the Remdesivir drug for COVID-19, has signed pacts with four more companies viz. Reddy Labs, Syngene and Zydus Cadila in India. Earlier, Gilead had already licensed Jubilant Life, Cipla and Hetero Drugs to manufacture and sell its intravenous drug Remdesivir for treatment of COVID-19. It may be recollected that Remdesivir has received emergency use authorisation (EUA) in the US, India and some other countries for the treatment of Covid-19 after preliminary results from two trials. Gilead’s terms and conditions for all 9 companies are the same. These companies can manufacture Remdesivir for distribution in 127 countries; largely low-income and lower-middle income countries. These licenses are royalty-free until the Public Health Emergency stays. The wider licensing should help much larger scale manufacture of the drug.